Homozygous mutation at cytochrome P4502D6 in an individual with schizophrenia: Implications for antipsychotic drugs, side effects and compliance

Irish Journal of Psychological Medicine

Volumn 14, Issue 1, 1997, Pages 38-39

  Gill, Michael ^a   Hawi, Ziarih ^a   Webb, Marcus ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

antipsychotic drugs; CYP2D6; cytochrome P450; genetics; side effects

Indexed keywords

CHLORPROMAZINE; CYTOCHROME P450; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; THIORIDAZINE;

ADULT; AKATHISIA; ARTICLE; CASE REPORT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MUTATION; PATIENT COMPLIANCE; PRESCRIPTION; SCHIZOPHRENIA; TREMOR;

EID: 0030891523     PISSN: 07909667     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0790966700002925     Document Type: Article

References (5)

1. Cholerton S, Daly A, Idle R. The role of individual human cytochrome P450 in drug metabolism and clinical response. TiPS 1992; 13: 434-9.
2. Gonzalez F. Human cytochromes P450 problems and prospects. TiPS 1992; 13: 346-52.
3. Meyer J, Woggon B, Baumann P, Meyer U. Clinical implications of slow sulphoxidation of thiroridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 1990; 39: 613-4.
4. Daly AK, Armstrong M, Monkman SC, et al. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1991; 1: 33-41.
5. Dahl-Puustinen M-L, Liden A, Alm C, Nordin C, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 78-81.